Home › Funds › Prosight Management, LP › JANX

Prosight Management, LP position in JANX

JANUX THERAPEUTICS INC · Health Care

Prosight Management, LP reported holding 2,943,200 shares of JANX (JANUX THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$50.9M, representing 9.87% of its reported portfolio and ranking #3 among its reported holdings. Prosight Management, LP has disclosed JANX holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)2.94M sh
Reported value held$50.86M
Portfolio Weight9.87%
First reportedQ3 2024
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Prosight Management, LP's JANX position evolved

Prosight Management, LP first disclosed a stake in JANX in Q3 2024 at 205,000 shares (US$9.3M). The position peaked in Q2 2026 at 3,804,481 shares, worth US$58.4M. Across 9 filings, Prosight Management, LP increased the stake 7 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,943,200 shares valued at US$50.9M — a reduction of -861,281 shares quarter over quarter.. Notable position changes include a 61% increase in Q4 2024 (shares fell 50% over the following quarter), a 109% increase in Q1 2025 (shares fell 14% over the following quarter), a 176% increase in Q4 2025 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 205.00K $9.31M New
Q4 2024 329.77K $17.66M Add
Q1 2025 689.90K $18.63M Add
Q2 2025 853.90K $19.73M Add
Q3 2025 865.35K $21.15M Add
Q4 2025 2.39M $33.02M Add
Q1 2026 3.55M $49.34M Add
Q2 2026 3.80M $58.44M Add
Q3 2026 2.94M $50.86M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JANX and 13F data

JANX (JANUX THERAPEUTICS INC) is a Health Care company. 26 other funds we track also report a position in JANX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$171.9M), TCG Crossover Management, LLC (US$27.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JANX

All JANX fund holders →

FAQ

How long has Prosight Management, LP held JANX?

Prosight Management, LP has disclosed JANX holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Prosight Management, LP's current position in JANX?

As of Q3 2026, Prosight Management, LP holds 2.94M shares of JANX (JANUX THERAPEUTICS INC), valued at $50.86M, representing 9.87% of its reported portfolio and ranking #3.

Has Prosight Management, LP been buying or selling JANX?

In the latest 13F filing (Q3 2026), Prosight Management, LP reduced its position in JANX. The position peaked in Q2 2026 at 3.80M shares.

Which other funds hold JANX?

Other major institutional holders of JANX include RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management, LLC, among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.